Study of Weekly DCF to Treat Advanced Gastric Cancer

Inclusion Criteria: * Age between 18 and 70 years * Patients with histologically confirmed, unresectable, recurrent and/or metastatic gastric adenocarcinoma * ECOG performance status ≤1,life expectancy more than 3 months, * Normal laboratory findings:absolute neutrophil count and platelet count ≥ 2.0×109/L and 80×109/L, respectively, hepatic function (total serum bilirubin ≤ UNL, transaminases ≤ 1.5 times upper normal limit) and renal function (calculated creatinine clearance ≥ 60 ml/min). * Measurable disease according to the RECIST. Exclusion Criteria: * Pregnant or lactating women * Serious uncontrolled diseases and intercurrent infection * The evidence of CNS metastasis * History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * Received other chemotherapy regimen after metastasis * Used taxane in adjuvant settings * Participated in other clinical trials.